Filtered By:
Specialty: Hematology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 228 results found since Jan 2013.

Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial
Conclusions: Based on AVERROES trial results, among patients with AF unsuitable for warfarin therapy, apixaban use was estimated to be associated with a mean medical cost avoidance of US$735 in a patient-year relative to aspirin. The primary driver was the significant reduction in ischemic stroke rate. The medical cost reduction associated with apixaban use was consistent in sensitivity analyses.
Source: Clinical and Applied Thrombosis/Hemostasis - February 27, 2015 Category: Hematology Authors: Amin, A., Deitelzweig, S., Jing, Y., Makenbaeva, D., Wiederkehr, D., Lin, J., Graham, J. Tags: Original Articles Source Type: research

Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.
In conclusion, warfarin treatment where patients spend a high proportion of time in the therapeutic range is safe and effective, and will continue to be a valid treatment option in the era of newer oral anticoagulants. PMID: 25716771 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 26, 2015 Category: Hematology Authors: Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A Tags: Thromb Haemost Source Type: research

Anticoagulation therapy in 2015: where we are and where we are going
Abstract Oral anticoagulants are a mainstay for the prevention and treatment of venous and arterial thrombosis. In 2015, the non-vitamin K oral anticoagulants (NOACs) are already replacing warfarin for many indications. Ongoing studies are focused on development of antidotes and specific reversal agents for the NOACs, and assessing their utility for prevention of cardiovascular events in patients with heart failure, coronary or peripheral artery disease, or embolic stroke of unknown source. This paper (a) lists the current indications for the NOACs; (b) reviews the current impact of the NOACs in each of these indi...
Source: Journal of Thrombosis and Thrombolysis - February 19, 2015 Category: Hematology Source Type: research

Pros and Cons of Vitamin K Antagonists and Non–Vitamin K Antagonist Oral Anticoagulants
This article discusses the advantages and disadvantages of VKAs and NOACs.[...]Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals:Table of contents  |  Abstract  |  Full text
Source: Seminars in Thrombosis and Hemostasis - February 19, 2015 Category: Hematology Authors: Riva, NicolettaAgeno, Walter Source Type: research

Comparative Efficacy and Safety of the Non–Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation
Semin Thromb HemostDOI: 10.1055/s-0035-1544156The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor (dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have been shown to be at least as efficacious and safe as conventional oral anticoagulants, such as the vitamin K antagonists (VKAs) (e.g., warfarin), for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Each NOAC has various advantages and specific features, and therefore decisions regarding appropriate stroke prevention require individual assessment of stroke and bleeding ri...
Source: Seminars in Thrombosis and Hemostasis - February 15, 2015 Category: Hematology Authors: Senoo, KeitaroLip, Gregory Y. H. Source Type: research

Individualized antithrombotic therapy.
Conclusion: An extensive therapeutic arsenal to interfere with clot formation requires an individualized approach considering the disease condition and co-morbidities of the patient, the anticoagulants' and patientcharacteristics. This review builds on and extens previous publications of the authors on this topic. PMID: 25597592 [PubMed - as supplied by publisher]
Source: Hamostaseologie - January 19, 2015 Category: Hematology Authors: Lüscher TF, Steffel J Tags: Hamostaseologie Source Type: research

Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
CONCLUSION: More than 75% of patients were adherent >80% during the first year. Patients with higher morbidity, including patients with a higher risk of stroke or bleeding, exhibited better adherence. This improvement may be attributable to more regular contact with the health care system. This article is protected by copyright. All rights reserved. PMID: 25594442 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 16, 2015 Category: Hematology Authors: Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA Tags: J Thromb Haemost Source Type: research

Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study
ConclusionMore than 75% of patients were adherent >80% during the first year. Patients with higher morbidity, including patients with a higher risk of stroke or bleeding, exhibited better adherence. This improvement may be attributable to more regular contact with the health care system.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - January 1, 2015 Category: Hematology Authors: Anders Gorst‐Rasmussen, Flemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, Gregory Y.H. Lip, Deirdre A. Lane Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation
Abstract Recent trials on novel oral anticoagulants (NOAC) in patients undergoing cardioversion showed that NOACs are as safe and effective as treatment with vitamin K antagonists in patients with atrial fibrillation undergoing electric or pharmacological cardioversion. We conducted an EMBASE and MEDLINE search for studies in which patients undergoing cardioversion were assigned to treatment with NOACs versus VKAs. We identified one prospective randomized study and three post hoc analysis of randomized trials which enrolled 2,788 controls that received NOACs and 1,729 patients that received VKAs. NOACs and VKA...
Source: Journal of Thrombosis and Thrombolysis - December 27, 2014 Category: Hematology Source Type: research

Pros and cons of new oral anticoagulants.
Authors: Bauer KA Abstract The availability of new oral anticoagulants (NOACs) targeting either thrombin (dabigatran etexilate) or factor Xa (rivaroxaban and apixaban) for the prevention and treatment of thrombosis has been highly anticipated. NOACs have major pharmacologic advantages over vitamin K antagonists (eg, warfarin), including rapid onset/offset of action, few drug interactions, and predictable pharmacokinetics, eliminating the requirement for regular coagulation monitoring. Regulatory agencies have approved several NOACs for specific indications based on the results of clinical trials demonstrating effic...
Source: Hematology ASH Education Program - November 11, 2014 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs.
Source: Thrombosis Journal - November 4, 2014 Category: Hematology Authors: Jonathan DouxfilsAnne TamigniauBernard ChatelainCatherine GoffinetJean-Michel DognéFrançois Mullier Source Type: research

Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.
Abstract Anticoagulants are effective at preventing and treating thrombosis, but can cause bleeding. For decades, vitamin K antagonists (VKAs) have been the only available oral anticoagulants. The development of non-VKA oral anticoagulants (NOACs), which inhibit either factor Xa or thrombin stoichiometrically, has provided alternatives to VKAs for several indications. The results of recent large-scale randomised controlled trials comparing NOACs with VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation (AF) have produced some unexpected results. As a group, NOACs showed similar effic...
Source: Thrombosis and Haemostasis - September 4, 2014 Category: Hematology Authors: Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS Tags: Thromb Haemost Source Type: research

Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation: A Real-World Setting
Conclusion: We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban.
Source: Clinical and Applied Thrombosis/Hemostasis - August 26, 2014 Category: Hematology Authors: Fontaine, G. V., Mathews, K. D., Woller, S. C., Stevens, S. M., Lloyd, J. F., Evans, R. S. Tags: Original Articles Source Type: research

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism, but little is known about rivaroxaban-related bleeding complications in daily care. Using data from a prospective, noninterventional oral anticoagulation registry of daily care patients (Dresden NOAC registry), we analyzed rates, management, and outcome of rivaroxaban-related bleeding. Between October 1, 2011, and December 31, 2013, 1776 rivaroxaban patients were enrolled. So far, 762 patients (42.9%) reported 1082 bleeding events during/within 3 days after last intake of rivaroxaban (58.9% mino...
Source: Blood - August 7, 2014 Category: Hematology Authors: Beyer-Westendorf, J., Forster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Kohler, C., Werth, S., Sahin, K., Tittl, L., Hansel, U., Weiss, N. Tags: Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations Source Type: research

Aspirin-Responsive, Migraine-Like Transient Cerebral and Ocular Ischemic Attacks and Erythromelalgia in JAK2-Positive Essential Thrombocythemia and Polycythemia Vera.
Abstract Migraine-like cerebral transient ischemic attacks (MIAs) and ocular ischemic manifestations were the main presenting features in 10 JAK2(V617F)-positive patients studied, with essential thrombocythemia (ET) in 6 and polycythemia vera (PV) in 4. Symptoms varied and included cerebral ischemic attacks, mental concentration disturbances followed by throbbing headaches, nausea, vomiting, syncope or even seizures. MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromela...
Source: Acta Haematologica - August 7, 2014 Category: Hematology Authors: Michiels JJ, Berneman Z, Gadisseur A, Lam KH, De Raeve H, Schroyens W Tags: Acta Haematol Source Type: research